Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Completes Dionex Buy, Acquires Sterilin

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said after the close of the market on Tuesday that it has completed the $2.1 billion purchase of chromatography firm Dionex through a short-form merger.

Today, Thermo Fisher also announced it has acquired Sterilin, a provider of single-use plastic products, for an undisclosed amount.

Pursuant to the terms of the Dionex merger, all shares of the company will be exchanged for $118.50 per share. Dionex's stock ceased trading on Nasdaq after the close of the market today, and will be delisted.

Thermo Fisher had completed the tender offer for Dionex last Friday, following clearance from the European Union.

Commenting on the Sterilin acquisition, Marc Casper, president and CEO of Thermo Fisher, said in a statement that it broadens the range of specialty laboratory products that the firm offers. The business will be integrated into Thermo Fisher's Laboratory Products and Services segment.

Based in South Wales, UK, Sterilin posted $35 million in revenues in 2010 and has about 270 employees. Its products serve the microbiology, life sciences, and clinical markets.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.